全覆膜自膨式金属支架治疗原位肝移植术后良性胆道狭窄:5年结局
这项前瞻性研究纳入41例原位肝移植术后吻合口良性胆道狭窄成人患者,评估全覆膜自膨式金属支架(FCSEMS)的长期疗效与安全性。按意向性分析,所有患者5年无支架放置概率为48.9%(95%CI 33.2%-64.7%),FCSEMS留置超过4个月的31例患者为60.9%(95%CI 43.6%-78.2%)。28例狭窄缓解者5年无狭窄复发概率为72.6%(95%CI 55.3%-90%),16例(39%)发生至少1次相关严重不良事件,最常见为胆管炎(n=10)。
要点
- FCSEMS治疗后5年,意向性分析下约半数患者仍无需支架。
- FCSEMS相关严重不良事件常见(39%),以胆管炎为主(n=10)。
- FCSEMS置入是肝移植术后良性胆道狭窄可行的长期治疗选择。
核心结论
- FCSEMS临时治疗肝移植术后良性胆道狭窄后5年,意向性分析下约半数患者仍无需支架。
- 支架相关严重不良事件(尤其胆管炎)常见。
- FCSEMS置入是肝移植术后良性胆道狭窄患者可行的长期治疗选择。
研究设计与样本
- 前瞻性研究,纳入41例年龄≥18岁、既往行原位肝移植、胆管造影确诊良性胆道狭窄且有ERCP支架置入指征的成人患者。
- 计划支架置入后4至6个月取出,随后随访至5年或狭窄复发。
- 长期结局包括无狭窄复发、无再次支架置入及支架相关严重不良事件。
主要发现
- 41例患者中,33例在FCSEMS取出后、8例在观察到完全远端迁移后开始长期随访。
- 意向性分析下,所有患者FCSEMS取出或观察到完全远端迁移后5年无支架概率为48.9%(95%CI 33.2%-64.7%)。
- 31例FCSEMS留置时间超过4个月的患者,5年无支架概率为60.9%(95%CI 43.6%-78.2%)。
- 28例FCSEMS取出时或观察到完全远端迁移时狭窄缓解(中位留置时间5.0个月)的患者,5年无狭窄复发概率为72.6%(95%CI 55.3%-90%)。
- 16例(39%)发生至少1次相关严重不良事件,最常见为胆管炎(n=10)。
临床怎么用
- 原文结论认为FCSEMS置入是肝移植术后良性胆道狭窄患者可行的长期治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Minimally invasive treatments of anastomotic benign biliary stricture (BBS) after orthotopic liver transplantation (OLT) include endoscopic placement of multiple plastic stents or fully covered self-expandable metal stents (FCSEMSs). No multiyear efficacy data are available on FCSEMS treatment after OLT. METHODS: We prospectively studied long-term efficacy and safety of FCSEMS treatment in adults aged ≥18 years with past OLT, cholangiographically confirmed BBS, and an indication for ERCP with stent placement. Stent removal was planned after 4 to 6 months, with subsequent follow-up until 5 years or stricture recurrence. Long-term outcomes were freedom from stricture recurrence, freedom from recurrent stent placement, and stent-related serious adverse events (SAEs). RESULTS: In 41 patients, long-term follow-up began after FCSEMS removal (n = 33) or observation of complete distal migration (CDM) (n = 8). On an intention-to-treat basis, the 5-year probability of remaining stent-free after FCSEMS removal or observation of CDM was 48.9% (95% confidence interval [CI], 33.2%-64.7%) among all patients and 60.9% (95% CI, 43.6%-78.2%) among 31 patients with over 4 months of FCSEMS indwell time. In 28 patients with stricture resolution at FCSEMS removal or observed CDM (median, 5.0 months indwell time), the 5-year probability of no stricture recurrence was 72.6% (95% CI, 55.3%-90%). Sixteen patients (39%) had at least 1 related SAE, most commonly cholangitis (n = 10). CONCLUSIONS: By 5 years after temporary FCSEMS treatment of post-OLT BBS, approximately half of all patients remained stent-free on an intention-to-treat basis. Stent-related SAEs (especially cholangitis) were common. FCSEMS placement is a viable long-term treatment option for patients with post-OLT BBS. (Clinical trial registration number: NCT01014390.).
引用
- Poley JW, Ponchon T, Puespoek A, et al. Fully covered self-expanding metal stents for benign biliary stricture after orthotopic liver transplant: 5-year outcomes. Gastrointest Endosc. 2020. PMID: 32417298. doi:10.1016/j.gie.2020.04.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。